Economic evaluation of human papillomavirus vaccination in the Global South: a systematic review

Saba Abidi (), Satyanarayana Labani (), Aastha Singh (), Smita Asthana () and Puneeta Ajmera ()
Additional contact information
Saba Abidi: Delhi Pharmaceutical Sciences and Research University
Satyanarayana Labani: Indian Council of Medical Research – National Institute of Cancer Prevention and Research
Aastha Singh: Delhi Pharmaceutical Sciences and Research University
Smita Asthana: Indian Council of Medical Research – National Institute of Cancer Prevention and Research
Puneeta Ajmera: Delhi Pharmaceutical Sciences and Research University

International Journal of Public Health, 2020, vol. 65, issue 7, No 13, 1097-1111

Abstract: Abstract Objectives Many reviews have been conducted on the economic evaluation of the HPV vaccine in global north countries. But there is a dearth of such reviews in the Global South countries. Hence, this systematic review aims to summarize studies done in these countries. Methods Four databases PubMed, Embase, Cochrane Library, and Google Scholar from 2009 to 2019 were searched for economic evaluations on HPV vaccination in the Global South countries. PRISMA guidelines were followed to include full-text articles. 40 original articles were shortlisted for full-text review. Results Studies had varied models, assumptions, and results according to different scenarios. Most studies concluded HPV vaccination to be cost-effective under varied scenarios and vaccine cost was the most influential parameter affecting the sensitivity analyses, consequently incremental cost-effectiveness ratio. A wide range in the cost-effectiveness ratio was observed in the included studies due to different study settings, populations, and inconsistencies in modeling practices (variations in methodological approaches). Conclusions This review suggests the introduction of HPV vaccination alone or in combination with screening according to different countries. The price of the vaccine should be economical and funds for the vaccine should be provided by public sector firms.

Keywords: Cost-effectiveness; Economic evaluation; Global South; HPV vaccination; ICER (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s00038-020-01431-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:ijphth:v:65:y:2020:i:7:d:10.1007_s00038-020-01431-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/00038

DOI: 10.1007/s00038-020-01431-1

Access Statistics for this article

International Journal of Public Health is currently edited by Thomas Kohlmann, Nino Künzli and Andrea Madarasova Geckova

More articles in International Journal of Public Health from Springer, Swiss School of Public Health (SSPH+)
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().